Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.10.2019 | Case report

Nivolumab/pembrolizumab

Interstitial lung diseases: 9 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Komiya K, et al. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thoracic Cancer 10: 1798-1804, No. 9, Sep 2019. Available from: URL: http://doi.org/10.1111/1759-7714.13149 - Japan Komiya K, et al. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thoracic Cancer 10: 1798-1804, No. 9, Sep 2019. Available from: URL: http://​doi.​org/​10.​1111/​1759-7714.​13149 - Japan
Metadaten
Titel
Nivolumab/pembrolizumab
Interstitial lung diseases: 9 case reports
Publikationsdatum
01.10.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-70492-8

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Rituximab

Case report

Tolvaptan

Case report

Mepolizumab

Case report

Multiple drugs

Case report

Azathioprine